What if you could give your weight loss journey a boost? GLP-1 receptor agonists are doctor-prescribed medications that facilitate weight loss by replicating a hormone that curbs your appetite. Their effectiveness is amplified when paired with consistent physical activity, balanced nutrition, and overall healthy lifestyle choices. By integrating GLP-1 into a comprehensive, holistic health plan one that embraces mental well-being and personalised guidance you can enhance your chances of achieving sustainable, long-term success. Nutrition While GLP-1 medications help suppress appetite, following a balanced, nutrient-dense eating plan is essential for maximizing benefits and reducing potential side effects. For best results, consider…
-
-
When was the last time you went on a trip and enjoyed the outdoors? As adults, reconnecting with nature becomes more difficult as responsibilities pile up. However, research shows that engaging with nature regularly helps reprogram your nervous system, which results in better pain management. The best part? You don’t even have to go to a forest. Any park in your local town will do. Nature Changes Your Brain’s Reaction to Pain — Even if It’s Virtual A 2025 study1 published in Nature Communications tested a simple hypothesis — does looking at nature truly change how your brain processes pain?…
-
Everyone’s comparing AI chatbots — but what happens when one of them is not a chatbot at all?
-
An index fund is a kind of passive investment that aims to mirror the performance of a specific index rather than trying to outperform it. Here we’ll look at what index mutual funds are, how they work, and all that you should know before investing in them. What are Index Funds? Every actively managed mutual fund like flexicap or ELSS has a benchmark or an index that it aims to outperform. In these options, fund managers try to beat the benchmark through their expert decision-making and research-driven stock selection. However, a classification of mutual funds called index funds takes a…
-
The 2025 NBA Playoffs are here with three big favorites and a pool of contenders ready to play the spoiler. The Boston Celtics are trying to become the league’s first back-to-back champion since the 2017-2018 Golden State Warriors. Boston ran over the league on their way to a championship last year, but the path won’t be so easy this season. The Cleveland Cavaliers earned the No. 1 seed in the East with a shocking 64-win season powered by their ‘core four’ of Donovan Mitchell, Evan Mobley, Darius Garland, and Jarrett Allen. The Oklahoma City Thunder were even better as the…
-
An application tracking system (ATS) is part of many organizations’ recruitment tech stack. Although they’re frequently seen in corporate settings, small businesses and mid-market companies also use them fairly extensively.
-
Image by Priscilla Du Preez Polyamory tends to spark strong reactions. For some, it’s seen as liberating—an honest approach to love that breaks free from outdated rules. For others, it raises eyebrows and invites assumptions, particularly one in particular: that polyamorous people are afraid of commitment. But here’s the twist. The more you listen to people in polyamorous relationships, the more you start to wonder if the exact opposite might be true. What if, rather than running from intimacy, they’re embracing a deeper form of it? What if polyamory doesn’t signal a fear of commitment, but an evolved way of…
-
Last week, we marked an important milestone in our SMB journey with the first-ever EMEA SMB Partner Advisory Board-a dynamic and insightful gathering of 51 partners who joined us for two days of deep discussions, strategy alignment, and collaborative workshops. A Powerful Start We kicked off with an inspiring keynote where José van Dijk emphasized the critical role SMBs play in Cisco’s strategy. I had the opportunity to expand on this, detailing our EMEA SMB vision and what the future holds. Agostino Santoni, our VP for EMEA South Europe, brought a sales perspective to the conversation and introduced one of…
-
Ligand Pharmaceuticals Incorporated LGND and Channel Therapeutics Corporation CHRO on Thursday signed a definitive merger agreement to combine Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. (collectively Pelthos) with CHRO Merger Sub Inc., a wholly owned subsidiary of Channel. The merger will be supported by $50 million in capital raised from a group of strategic investors led by Murchinson. Under the merger agreement, Channel will acquire 100% of Pelthos’ issued and outstanding equity interests, change its name to Pelthos Therapeutics, and trade on the NYSE American exchange under the ticker PTHS. Also Read: Analyst Sees Big Upside In…
-
United States Secretary of State Marco Rubio — GETTY IMAGES VIA AFP PARIS, France — US Secretary of State Marco Rubio was in Paris on Thursday to meet French President Emmanuel Macron about crafting a Ukraine ceasefire, as Washington and Europe seek common ground on ending the fighting. Top Ukrainian officials were also in the French capital on Thursday to meet EU and US delegations, President Volodymyr Zelensky’s chief of staff said, without specifying who. Article continues after this advertisement Rubio and Keith Kellogg, US President Donald Trump’s special envoy to Ukraine, arrived in Paris, with US envoy Steve Witkoff…